Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Delays Decision on Diabetes Treatment Onglyza

By Pharmaceutical Processing | April 23, 2009

NEW YORK (AP) — Drugmakers Bristol-Myers Squibb Co. and AstraZeneca PLC said Thursday federal regulators need more time to review their application for the diabetes treatment Onglyza. The Food and Drug Administration has extended its deadline for making a decision on the drug by three months, pushing it back to July 30 from April 30. Earlier this month, an FDA panel said the drug appears free from heart problems seen with similar drugs but added that long-term studies should be done after approval to confirm its safety. The FDA is not required to follow the group’s recommendation, though it normally does. The drug treats type 2 diabetes and, if approved, will compete with Merck & Co.’s blockbuster Januvia, which had sales of $1.4 billion last year. Analysts have estimated Onglyza’s annual sales to be anywhere from $300 million annually to over $1 billion if approved. New York-based Bristol-Myers and London-based AstraZeneca submitted their new drug application June 30. The companies said in a statement they continue to work closely with the FDA. They were encouraged by the advisory panel’s recommendation, and they “remain confident in the comprehensiveness of our overall development program and submission” for Onglyza. Bristol-Myers shares rose 3 cents to $19.84 in morning trading Thursday. AstraZeneca shares, meanwhile, were down 3 cents to $33.37.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE